Posts

Economic Factors Shape Rheumatoid Arthritis Trial Outcomes

Recruiting patients from lower-income countries is associated with higher placebo response rates in rheumatoid arthritis trials, a recent study finds. Medscape Medical News source https://www.medscape.com/viewarticle/economic-factors-shape-rheumatoid-arthritis-trial-outcomes-2025a1000mzd?src=rss

All-Cause Mortality Benefit Claimed for Vericiguat in HF

In heart failure with reduced ejection fraction, vericiguat was associated with a reduction in all-cause death. But are the data strong enough to make the drug a new addition to the standard of care? Medscape Medical News source https://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9?src=rss

Baxdrostat: A “Game Changer” for Hypertension?

A new class of antihypertensive agent that blocks the production of aldosterone has shown impressive results in patients with resistant or uncontrolled hypertension. Medscape Medical News source https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7?src=rss

Reducing Blood Pressure Meds in Older Adults Not Supported

Despite observational evidence supporting a low-dose approach to antihypertensive therapy in the old and frail, a randomized prospective trial finds no clear benefits for doing so. Medscape Medical News source https://www.medscape.com/viewarticle/stepping-down-hypertensive-therapy-not-beneficial-frail-2025a1000mys?src=rss

Is Warfarin Still an Option for Frail Patients With AF?

A meta-analysis shows newer anticoagulants are safer than warfarin, especially for serious bleeding complications like intracranial hemorrhage. Medscape Medical News source https://www.medscape.com/viewarticle/warfarin-still-option-frail-patients-atrial-fibrillation-2025a1000myp?src=rss

High-Dose Flu Vax Reduces Hospitalizations, Study Finds

Trials reinforce calls for vaccination to be part of cardiovascular prevention strategies. Medscape Medical News source https://www.medscape.com/viewarticle/largest-ever-individually-randomized-trials-show-high-dose-2025a1000mym?src=rss

Digitoxin Lowers HF Events in Symptomatic Patients

Study results show mortality benefit from low-dose digitoxin for heart failure in symptomatic patients with reduced ejection fraction. Medscape Medical News source https://www.medscape.com/viewarticle/new-data-support-digitoxin-comeback-some-heart-failure-2025a1000myi?src=rss